de novo design in the synthetically accessible compounds universe

webinar

Tue, 23 Feb 2016, 16:00 CET (Berlin)

Dr. Christian Lemmen, BioSolveIT GmbH, St. Augustin, Germany

de novo design in the synthetically accessible compounds universe

No matter how big your in-house library and no matter how many compounds you acquire as supplement, it merely scratches the surface of what chemists are capable of synthesizing. Recent publications indicate that the majority of chemical space is defined on the basis of only 50-70 robust chemical reactions. We have used these to compile a Chemical Space comprising billions of virtual compounds with high likelihood of straight forward synthetic access. We make this literature-derived collection publicly available and also provide a unique similarity search method capable to explore such wealth of data. Imagine de novo design of (a) hit expansion libraries, (b) follow-up series and (c) fragment evolution designs from within an all accessible compound space. We will demonstrate how this can become reality.

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on